A new cholinergic mechanism for antipsychotics: emraclidine and M4 muscarinic receptors

Affiliations

¹ Department of Psychological Medicine, Royal London Hospital, London E1 1BB, UK. Electronic address: john.cookson1@nhs.net.
² Department of Psychological Medicine, Royal London Hospital, London E1 1BB, UK.

Comment

John Cookson et al. Lancet. 2022.

. 2022 Dec 17;400(10369):2159-2161.

doi: 10.1016/S0140-6736(22)02421-7.

¹ Department of Psychological Medicine, Royal London Hospital, London E1 1BB, UK. Electronic address: john.cookson1@nhs.net.
² Department of Psychological Medicine, Royal London Hospital, London E1 1BB, UK.

No abstract available

Comment on

Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial.
Krystal JH, Kane JM, Correll CU, Walling DP, Leoni M, Duvvuri S, Patel S, Chang I, Iredale P, Frohlich L, Versavel S, Perry P, Sanchez R, Renger J. Krystal JH, et al. Lancet. 2022 Dec 17;400(10369):2210-2220. doi: 10.1016/S0140-6736(22)01990-0. Lancet. 2022. PMID: 36528376 Clinical Trial.